Even though studies have already proven that recombinant human TRAIL enhances the tumor sensitivity to chemotherapy/targeted therapy/radiotherapy in various cancer types, this may not apply to KRAS-mutated cancers (Yuan et al., 2018; von Karstedt and Walczak, 2020; Pal et al., 2016). This evidence concerns the gene TNFSF10 and neoplasm.